Literature DB >> 28052629

Pathology of non-alcoholic fatty liver disease.

Pierre Bedossa1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of lesions ranging from steatosis (Non-alcoholic Fatty Liver or NAFL) to a complex pattern with hepatocellular injury and inflammation (non-alcoholic steatohepatitis; NASH) in the absence of alcohol intake. However, it is increasingly clear that intermediate patterns may exist. The histopathological evaluation of liver biopsy samples is central in the diagnosis of NAFLD and NASH in the absence of sufficiently accurate non-invasive tests because a precise definition of each group is a key issue. When at least 5% of hepatocytes display steatosis, patients can be defined as having NAFLD in an appropriate clinical context. When, in addition, lobular inflammation and liver cell clarification/ballooning are present, then the lesion is usually defined as NASH. Evaluation of the stage of fibrosis is even more fundamental than necroinflammation since it is the main prognostic factor of this disease. Semi-quantitative histological scoring systems have been proposed for NAFLD, but they are not useful in clinical practice and each has certain limitations. For comprehensive purposes, we suggest describing histopathological lesions in NAFLD using the SAF (Steatosis, Activity, Fibrosis) score which assesses separately the grade of steatosis (S, from S0 to S3), the grade of activity (A from A0 to A4 by adding grades of ballooning and lobular inflammation, both from 0 to 2) and the stage of fibrosis (F from F0 to F4).
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  fibrosis; liver biopsy; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis

Mesh:

Year:  2017        PMID: 28052629     DOI: 10.1111/liv.13301

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  81 in total

1.  Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.

Authors:  Noha F Hassan; Somaia A Nada; Azza Hassan; Mona R El-Ansary; Muhammad Y Al-Shorbagy; Rania M Abdelsalam
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 2.  MR elastography of liver: current status and future perspectives.

Authors:  Ilkay S Idilman; Jiahui Li; Meng Yin; Sudhakar K Venkatesh
Journal:  Abdom Radiol (NY)       Date:  2020-07-23

3.  Mixture of blackberry leaf and fruit extracts alleviates non-alcoholic steatosis, enhances intestinal integrity, and increases Lactobacillus and Akkermansia in rats.

Authors:  Sunmin Park; Song Mi Cho; Bo Ram Jin; Hye Jeong Yang; Qiu Jing Yi
Journal:  Exp Biol Med (Maywood)       Date:  2019-11-21

4.  Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.

Authors:  Fanhong Zeng; Yue Zhang; Xu Han; Min Zeng; Yi Gao; Jun Weng
Journal:  Front Immunol       Date:  2021-01-26       Impact factor: 7.561

5.  Design and in vivo activity of A3 adenosine receptor agonist prodrugs.

Authors:  R Rama Suresh; Shanu Jain; Zhoumou Chen; Dilip K Tosh; Yanling Ma; Maren C Podszun; Yaron Rotman; Daniela Salvemini; Kenneth A Jacobson
Journal:  Purinergic Signal       Date:  2020-07-27       Impact factor: 3.765

Review 6.  Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights.

Authors:  Kristen Stephenson; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Joanne Thomson; Gianfranco Alpini; Heather Francis
Journal:  Gene Expr       Date:  2017-11-02

Review 7.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

8.  Oxidized linoleic acid metabolites induce liver mitochondrial dysfunction, apoptosis, and NLRP3 activation in mice.

Authors:  Susanne Schuster; Casey D Johnson; Marie Hennebelle; Theresa Holtmann; Ameer Y Taha; Irina A Kirpich; Akiko Eguchi; Christopher E Ramsden; Bettina G Papouchado; Craig J McClain; Ariel E Feldstein
Journal:  J Lipid Res       Date:  2018-07-03       Impact factor: 5.922

9.  Chronic consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats.

Authors:  Sugeedha Jeyapal; Uday Kumar Putcha; Venkata Surekha Mullapudi; Sudip Ghosh; Anil Sakamuri; Suryam Reddy Kona; Sai Santosh Vadakattu; Chandana Madakasira; Ahamed Ibrahim
Journal:  Eur J Nutr       Date:  2017-07-04       Impact factor: 5.614

Review 10.  Liver-on-a-Chip Models of Fatty Liver Disease.

Authors:  Shabir Hassan; Shikha Sebastian; Sushila Maharjan; Ami Lesha; Anne-Marie Carpenter; Xiuli Liu; Xin Xie; Carol Livermore; Yu Shrike Zhang; Ali Zarrinpar
Journal:  Hepatology       Date:  2020-02       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.